To date, the p300/CBP bromodomain inhibitor CCS1477 is the only inhibitor currently in phase 1b/2a clinical trials for the treatment of hematological malignancies and advanced drug-resistant prostate cancer37–39. This evidence concerns the gene EP300 and hematologic disorder.